Bamlanivimab no longer recommended due to COVID variants in Colorado
The monoclonal antibody bamlanivimab is no longer recommended as monotherapy for the treatment of COVID-19 in Colorado. The prevalence of B.1.427/B.1.429 variants is now estimated to be greater than 20%…